21 citations
,
January 2008 in “Journal of Pediatric Endocrinology and Metabolism” This study found that combined treatment with anastrozole and cyproterone acetate improved the adult height prognosis in testotoxicosis, as observed in two brothers, with good tolerance reported.
October 2025 in “Journal of the Endocrine Society” In this case report, hyperandrogenism, including hirsutism and elevated testosterone, in a post-menopausal woman on anastrozole for breast cancer may be attributed to the drug after ruling out other serious causes like ovarian hyperthecosis.
67 citations
,
October 2005 in “Annals of Oncology” This review found that fulvestrant is well tolerated in postmenopausal women with hormone receptor-positive advanced breast cancer, showing lower incidence of joint disorders than non-steroidal aromatase inhibitors.
7 citations
,
April 2023 in “Biomedicines” This study found that sex hormones, specifically non-aromatizable androgens like DHT and A/T, significantly increase inflammatory cytokine expression in human adipocytes when stimulated by LPS.
6 citations
,
August 2020 in “JCRPE” This report presents a case of familial male-limited precocious puberty with a novel LHCGR gene mutation, where a boy responded well to treatment with bicalutamide and anastrozole.
5 citations
,
January 2020 in “in Vivo” This study found that administering testosterone to pregnant rats altered connexin 26 and connexin 43 expression in the uterus, which could disrupt embryo implantation and cause early pregnancy loss.
3 citations
,
January 2018 in “Frontiers in bioscience” This retrospective analysis reported significant increases in testosterone levels in men with testosterone deficiency using the Daily Subcutaneous Testosterone method combined with hCG and anastrozole, indicating its potential as a treatment option.
2 citations
,
May 2025 in “Frontiers in Pharmacology” In this study, analysis of FDA data revealed a substantial risk of dermatologic adverse events with aromatase inhibitors, especially anastrozole and exemestane, highlighting the importance of dermatologic monitoring during such therapies.
1 citations
,
November 2024 in “Expert Opinion on Drug Safety” In this retrospective pharmacovigilance study, researchers analyzed over 7,900 adverse event reports related to aromatase inhibitors, identifying common side effects and toxicological mechanisms to highlight potential safety concerns in treating postmenopausal hormone receptor-positive breast cancer.
1 citations
,
September 2020 in “Pediatric Dermatology” In this case report, two adolescents developed androgenetic alopecia after treatment with anastrozole for idiopathic short stature, suggesting this potential side effect should be considered in pediatric patients using aromatase inhibitors.
This research explores the pathogenesis of benign prostatic hyperplasia and evaluates the combined effect of finasteride and anastrozole in treating BPH in a rat model, but reports no new results yet.
This study is designed to explore the pathogenesis of BPH and assess the effectiveness of combining finasteride and anastrozole as a treatment in rats, with a focus on genetic polymorphisms and hormone regulation.
This study found that combining finasteride and anastrozole was more effective in preventing and treating benign prostatic hyperplasia in rats than using either drug alone.
January 2025 in “Biomedicines” In this study, female rats given high doses of testosterone showed decreased endometrial thickness and lower mRNA levels of components in the LIF signalling pathway, indicating that excessive testosterone may negatively impact endometrial receptivity and potentially affect fertility.
March 2024 in “The journal of sexual medicine” This case study observed that in four middle-aged men with ejaculation disorders, therapy with human chorionic gonadotropin (hCG) alone or combined with recombinant follicle-stimulating hormone (rFSH) improved sexual desire, semen volume, and various other symptoms, although some experienced elevated estradiol levels and hair loss.
November 2022 in “Journal of the Endocrine Society” This case study reports that in an 8-year-old male, a pituitary adenoma causing isolated high LH secretion led to early testosterone-driven puberty without typical testicular enlargement, highlighting the differential roles of LH and FSH in pubertal development.
April 2019 in “Journal of the Endocrine Society” This case report documents successful virilization, including penile length increase, in a boy with partial androgen insensitivity syndrome using high-dose testosterone combined with anastrozole.
June 2017 in “Reactions Weekly” Some breast cancer treatments caused long-term hair loss in women, similar to a condition called alopecia areata.
February 2013 in “Journal of The American Academy of Dermatology” Hair loss is a common side effect of hormone treatments for cancer.
3 citations
,
September 2020 in “Journal of developmental and behavioral pediatrics/Journal of developmental & behavioral pediatrics” This case report describes a 4-year-old boy with autism and a rare condition causing precocious puberty, where treatment for hyperandrogenism unexpectedly intensified his aggressive behavior.
January 2024 in “Life sciences” This study observed that in spontaneously hypertensive rats, testosterone's effects on endothelium-dependent vasodilation involved reduced nitric oxide levels, increased oxidative stress, and greater reliance on endothelium-dependent hyperpolarization, with variations in these responses noted when testosterone was combined with either anastrozole or finasteride.
2 citations
,
October 2023 in “Skin Health and Disease” This case report describes a rare instance of alopecia neoplastica, where breast cancer metastasized to the scalp, which can be mistakenly diagnosed as alopecia areata.
24 citations
,
October 2012 in “The International Journal of Biochemistry & Cell Biology” In this study, testosterone protected female embryonic heart cells from metabolic stress by being converted into metabolites that activate estrogen receptors and up-regulate certain mitochondrial channel proteins.
October 2025 in “Journal of the Endocrine Society” This case study reported that sudden hyperandrogenism in postmenopausal women may indicate hormonally active ovarian tumors such as Leydig cell tumors, which can be effectively treated with surgery.
September 2024 in “International Journal of Molecular Sciences” This study found that administering a supraphysiological dose of testosterone to female rats significantly reduced estrogen and progesterone levels, disrupted sex steroid receptor expression, and interfered with the embryonic implantation window, indicating potential implications for androgen-related endometrial conditions.
April 2019 in “Journal of the Endocrine Society” This study found that in male mouse pancreatic islet β cells, testosterone enhances glucose-stimulated insulin secretion by being locally converted into dihydrotestosterone and estradiol.
December 2013 in “Estudo Geral (Universidade de Coimbra)” This research investigated the design and synthesis of steroid-based compounds as aromatase inhibitors for breast cancer, finding that certain structural modifications significantly enhance their inhibitory potency.
10 citations
,
July 2011 in “Archives of Pharmacal Research” 
19 citations
,
May 2013 in “Annals of Oncology” This study observed that aromatase inhibitors caused hair loss in menopausal women with breast cancer, mimicking male pattern baldness rather than female androgenetic alopecia.
50 citations
,
December 2006 in “Bone” This study found that the steroidal aromatase inhibitor exemestane stimulated proliferation of human osteoblast cells, suggesting both androgen receptor-dependent and independent pathways are involved.